These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29098997)

  • 1. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
    Dela AI; Tank NKD; Singh AP; Piparva KG
    Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot.
    Piparva KG; Jansari G; Singh AP
    Perspect Clin Res; 2018; 9(4):165-169. PubMed ID: 30319946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
    Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
    Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in central India.
    Hire R; Kale AS; Dakhale GN; Gaikwad N
    Mediterr J Hematol Infect Dis; 2014; 6(1):e2014061. PubMed ID: 25237474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.
    Mpagama SG; Mvungi HC; Mbelele PM; Semvua HH; Liyoyo AA; de Guex KP; Sloan D; Kibiki GS; Boeree M; Phillips PPJ; Heysell SK
    Pilot Feasibility Stud; 2023 Apr; 9(1):55. PubMed ID: 37005695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions in tuberculosis and management.
    Prasad R; Singh A; Gupta N
    Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions & drug interactions in MDR-TB patients.
    Gupta A; Kumar V; Natarajan S; Singla R
    Indian J Tuberc; 2020 Dec; 67(4S):S69-S78. PubMed ID: 33308674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.
    Lv X; Tang S; Xia Y; Wang X; Yuan Y; Hu D; Liu F; Wu S; Zhang Y; Yang Z; Tu D; Chen Y; Deng P; Ma Y; Chen R; Zhan S
    PLoS One; 2013; 8(6):e65037. PubMed ID: 23750225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multidrug-resistant tuberculosis in Thailand.
    Maranetra KN
    Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.
    Hamusse SD; Teshome D; Hussen MS; Demissie M; Lindtjørn B
    BMC Public Health; 2016 Jul; 16():593. PubMed ID: 27430266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambispective study of adverse drug reactions in multi-drug resistant tuberculosis patients in Warangal, Telangana.
    Fatima S; Syeda MF; Adla N; Devi R
    Lung India; 2021; 38(4):330-337. PubMed ID: 34259171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center.
    Mukati S; Julka A; Varudkar HG; Singapurwala M; Agrawat JC; Bhandari D; Jain A
    Indian J Tuberc; 2019 Jul; 66(3):358-363. PubMed ID: 31439180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
    Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
    Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China.
    Wang J; Pang Y; Jing W; Chen W; Guo R; Han X; Wu L; Yang G; Yang K; Chen C; Jiang L; Cai C; Dou Z; Diao L; Pan H; Wang J; Du F; Xu T; Wang L; Li R; Chu N
    Infect Drug Resist; 2019; 12():763-770. PubMed ID: 31040707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis.
    Jain K; Desai M; Solanki R; Dikshit RK
    J Pharmacol Pharmacother; 2014 Apr; 5(2):145-9. PubMed ID: 24799815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.